Xalkori — Crizotinib 250 mg (60 Capsules)
Xalkori (Crizotinib) is an innovative antineoplastic medication belonging to the group of protein tyrosine kinase inhibitors. It is designed for targeted therapy of specific forms of non-small cell lung cancer (NSCLC). The active substance — crizotinib — blocks the activity of ALK, ROS1, and MET receptors, which stimulate the growth and division of malignant cells. As a result, the drug effectively slows disease progression and contributes to tumor shrinkage.
Manufacturer: Pfizer. Xalkori was the first drug to change the standard of care for patients with ALK-positive status, providing significantly higher survival rates and quality of life compared to traditional chemotherapy.
Key Features:
- ✅ Targeted Action: Specifically attacks cancer cells with specific genetic mutations (ALK or ROS1), with minimal damage to healthy tissues.
- ✅ Clinical Efficacy: Proven significant increase in progression-free survival.
- ✅ Convenience: Oral administration allows patients to undergo treatment at home.
Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 21.04.2026
Similar products
What Customers Say
No reviews yet
Your review can be the first!